A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination With Atezolizumab Compared With Atezolizumab Alone in Subjects With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer

Trial Profile

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination With Atezolizumab Compared With Atezolizumab Alone in Subjects With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Daratumumab (Primary) ; Atezolizumab
  • Indications Carcinoma; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms CALLISTO
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 20 Jul 2017 Planned End Date changed from 30 Nov 2018 to 4 Jan 2019.
    • 23 Jun 2017 Planned End Date changed from 25 Jan 2019 to 30 Nov 2018.
    • 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top